Newly Diagnosed With Uterine Cancer: What Lynch Syndrome Testing Means for You
Uterine cancer is one of the most common Lynch syndrome-associated cancers. Many patients are not aware of this connection. This page explains what it means and what usually happens next.
What You Should Know About the Connection Between Uterine Cancer and Lynch Syndrome
- Uterine (endometrial) cancer is the second most common Lynch syndrome-associated cancer after colorectal cancer. Approximately 2-3% of uterine cancers are caused by Lynch syndrome.
- NCCN recommends that all uterine cancer patients be offered genetic counseling and consideration of Lynch syndrome testing.
- Like colorectal cancer, uterine tumors are often tested for MSI/MMR status as a first screening step. An MSI-High result typically prompts germline genetic testing.
- A Lynch syndrome diagnosis has implications beyond your own cancer — it affects surveillance for other cancer types and raises questions for first-degree relatives.
What Hereditary Testing Means After a Uterine Cancer Diagnosis
Lynch syndrome is caused by mutations in mismatch repair genes (MSH2, MLH1, MSH6, PMS2, EPCAM). Among these, MSH6 and PMS2 mutations are particularly associated with uterine cancer risk — sometimes more strongly than colorectal cancer risk.
Women with Lynch syndrome face a significantly elevated lifetime risk of uterine cancer — estimates range from 15-60% depending on which gene is mutated — compared to approximately 3% in the general population.
What Usually Happens Next
If your tumor has not been tested for MSI/MMR status, ask your gynecologic oncologist. Universal tumor testing is recommended by NCCN for uterine cancer patients.
If Lynch syndrome is confirmed through germline testing, surveillance recommendations extend beyond gynecologic cancer — colonoscopy and other screenings are also typically recommended.
Why Uterine Cancer Can Trigger Lynch Syndrome Evaluation
Uterine cancer as a Lynch sentinel cancer
In some Lynch syndrome families, uterine cancer appears before colorectal cancer — making it a sentinel diagnosis that identifies the hereditary pattern. This is why genetic evaluation is recommended even when there is no colorectal cancer history.
MSH6 and PMS2 mutations and uterine risk
Among Lynch syndrome genes, MSH6 and PMS2 mutations carry particularly elevated uterine cancer risk, sometimes higher than colorectal cancer risk for these specific variants. A comprehensive panel will identify which gene is affected.
If you have already had a hysterectomy
A Lynch syndrome diagnosis still has implications after a hysterectomy — for colonoscopy surveillance, other cancer types associated with Lynch syndrome, and for your relatives who may carry the mutation.
Germline testing after MSI-High tumor results
As with colorectal cancer, an MSI-High or MMR-deficient uterine tumor is a signal that germline Lynch syndrome testing may be indicated — not a diagnosis. Germline testing confirms whether the mutation is heritable.
What a Lynch Syndrome Diagnosis Means for Your Family
If Lynch syndrome is confirmed, first-degree relatives each have a 50% chance of carrying the same mutation. For female relatives, the implications include both colorectal and uterine cancer risk. For male relatives, colorectal cancer risk is the primary concern.
The specific surveillance recommendations for relatives depend on which Lynch syndrome gene is affected. A genetic counselor can provide personalized guidance for your family.
- First-degree relatives (parents, siblings, children) — 50% chance if mutation confirmed
- Female relatives face elevated uterine and colorectal cancer risk
- Male relatives primarily face elevated colorectal cancer risk
- Surveillance recommendations differ by which MMR gene is mutated
How LifeShield Can Help
Lynch syndrome germline panel
Covers MSH2, MLH1, MSH6, PMS2, EPCAM, and all clinically significant Lynch-associated genes
Genetic counseling
Review of your tumor testing, family history, and clinical picture — pre-test and post-test
Multi-cancer surveillance guidance
Lynch syndrome affects more than one cancer type — your counselor will explain what surveillance is recommended beyond gynecologic cancer
Family cascade support
Guidance for relatives who want to understand their own Lynch syndrome risk
Reviewed by LifeShield Medical Team · Last reviewed March 2026
Frequently Asked Questions
NCCN recommends that all patients with uterine cancer be offered genetic counseling and consideration of Lynch syndrome evaluation. Universal tumor MSI/IHC testing is recommended, with germline testing indicated based on results and family history.
MSH6 and PMS2 mutations carry particularly elevated uterine cancer risk among the Lynch syndrome genes. MSH2 and MLH1 mutations also raise uterine cancer risk. A comprehensive germline panel tests all five Lynch syndrome genes.
No. Lynch syndrome is associated with elevated risk for colorectal, uterine, ovarian, stomach, small intestine, urinary tract, bile duct, and some other cancers. The specific risk profile depends on which gene mutation is present.
Yes. A Lynch syndrome diagnosis after a hysterectomy still has implications for colonoscopy and other cancer surveillance, and for first-degree relatives who may carry the same mutation.
Most eligible patients qualify for coverage when NCCN criteria are met. A uterine cancer diagnosis with MSI-High or MMR-deficient tumor results typically meets those criteria. LifeShield provides insurance support and superbill assistance for all patients.
Ready to Take the Next Step?
When you are ready, a licensed genetic counselor can help you understand your options and build a clear plan.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is based on published NCCN clinical guidelines and peer-reviewed research. Always consult a qualified healthcare provider for medical decisions. LifeShield content is reviewed by board-certified genetic counselors.